Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZENTALIS PHARMACEUTICALS, INC.

(ZNTL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zentalis Pharmaceuticals in Collaboration Agreement With GlaxoSmithKline

04/12/2021 | 06:39am EDT

By Chris Wack

Zentalis Pharmaceuticals Inc. said it has entered into a clinical collaboration agreement with GlaxoSmithKline PLC.

Zentalis said it will evaluate the combination of ZN-c3, an oral WEE1 inhibitor product candidate, and Zejula niraparib, GlaxoSmithKline's polymerase PARP inhibitor, in patients with advanced epithelial ovarian cancer.

Zentalis is currently conducting clinical studies with ZN-c3 both as a monotherapy and in combination with certain standard of care therapies.

Under the terms of the non-exclusive collaboration, Zentalis is responsible for conducting the study, with GlaxoSmithKline providing all required doses of niraparib. Zentalis will maintain full ownership of ZN-c3.

Zentalis shares were up 21% to $45.21 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

04-12-21 0839ET

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC 0.34% 1344.2 Delayed Quote.-0.18%
ZENTALIS PHARMACEUTICALS, INC. -4.33% 54.85 Delayed Quote.10.38%
All news about ZENTALIS PHARMACEUTICALS, INC.
04/20EMPIRE STATE REALTY TRUST  : Signs Up Zentalis Pharmaceuticals at 1359 Broadway ..
MT
04/20GAIN THERAPEUTICS  : Forms Multi-Target Drug Discovery Partnership with Zentalis..
MT
04/13ZENTALIS PHARMACEUTICALS  : SVB Leerink Adjusts Zentalis Pharmaceuticals' Price ..
MT
04/12SECTOR UPDATE : Health Care Stocks Slip as Midday Gains Evaporate
MT
04/12SECTOR UPDATE : Health Care Stocks Drifting Higher This Afternoon
MT
04/12ZENTALIS PHARMACEUTICALS  : Unveils Clinical Collaboration Deal With GlaxoSmithK..
MT
04/12Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreem..
GL
04/12Zentalis Pharmaceuticals in Collaboration Agreement With GlaxoSmithKline
DJ
04/10Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late..
GL
04/06ZENTALIS PHARMACEUTICALS, INC.  : Termination of a Material Definitive Agreement..
AQ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -167 M - -
Net cash 2021 217 M - -
P/E ratio 2021 -13,9x
Yield 2021 -
Capitalization 2 368 M 2 368 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 124
Free-Float 88,7%
Chart ZENTALIS PHARMACEUTICALS, INC.
Duration : Period :
Zentalis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZENTALIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 66,50 $
Last Close Price 54,85 $
Spread / Highest target 36,7%
Spread / Average Target 21,2%
Spread / Lowest Target 14,9%
EPS Revisions
Managers and Directors
NameTitle
Anthony Y. Sun Executive Chairman, President & CEO
Melissa B. Epperly Chief Financial Officer
Orna Bornstein Vice President-Clinical Operations
Kevin D. Bunker Chief Operating Officer
Karan S. Takhar Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ZENTALIS PHARMACEUTICALS, INC.10.38%2 368
GILEAD SCIENCES, INC.12.67%83 740
WUXI APPTEC CO., LTD.10.67%59 429
VERTEX PHARMACEUTICALS-9.51%55 364
REGENERON PHARMACEUTICALS0.43%49 948
BIONTECH SE109.48%41 245